Core One Labs Inc C.COOL

Alternate Symbol(s): CLABF

Healthcare Cannabis

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.

CSE:COOL - Post by User

Core One Labs Inc

Bullboard Posts

Comment by Straniuson Jun 28, 2017 7:10pm

293 Views

Post# 26416639

RE:Updated Cap Structure & List of Participants After PP Close

LDS management updated the current Share Structure on their website with new data as of yesterday here. The management numbers match what I posted earlier (below):

User image

My numbers of ~85.1M basic shares outstanding and ~117.5M fully diluted shares o/s (from this morning's post) agree with management except for 3 key differences:

They continue to count the future obligation to issue shares to Dr. Sanderson on patent receipt as part of existing share dilution (which I think is technically incorrect as that milestone has not transpired)
They show total broker units issued for the May 31 and June 26 PP of 1,048,460 at $0.50/unit. I'm unclear if these units represent the broker's right to acquire 1 LDS share and 1 LDS warrant with a $0.75 strike price for $0.50/unit or if these are merely the right to acquire 1 LDS share for $0.50/share. I've assumed the former (more dilutive) but asked management to clarify.
Management's table reveals that up to yesterday there were only 189,000 warrants exercised during June from the Aug 25, 2017 tranche. This tells me that all remaining warrant holders are opting not to sell at these low prices and are waiting for higher future prices. Also, management exercised 30,000 warrants from the July 13, 2017 tranche (these will ALL need to be exercised in the next 2 weeks by management (else they expire) which will generate a cash inflow of C$341K - note that I said exercised by management, not sold by management - BIG difference).

Stranius wrote: Ok as promised, below is an updated cap structure after yesterday's PP close announcement. Keep in mind this does not include any June warrant exercise transactions that we won't know about until the company files it's June monthly report no later than the 5th trading day of July.

https://investorshub.advfn.com/uimage/uploads/2017/6/28/lppxo2017-06-27_LDS_Cap_Struct.jpg

Incidentally, Form 9 which lists the participants in this most recent PP was also released and is available here:

https://thecse.com/sites/default/files/CSE_Form_9_Non-Brokered_PP_Close_Signed.pdf

@artfuldodger, the fully realized shares outstanding figure you referenced in your earlier post of 135 million is probably coming from my May 16 post here. That post included a catalyst table that went out to Dec 2017 and assumed LDS issued share (and cash) payments to NHMC, CSPA as well as the CEO's of LDS Agrotech and LDS Scientific based on the May 4 press release here. I consider that table to be somewhat dated based on newer information that has come to light since that post. I've been waiting for the COO issuance to rework that table and update the list of catalysts. They are all intertwined and triggered off the receipt of the COO and the Business License.

As of right now, there are ~85.1M shares outstanding and fully diluted share count is ~117.5M. Upcoming payments to NHMC, CSPA as well as the CEO's of LDS Agrotech and LDS Scientific over the next month (recall that July 31, 2017 is a trigger point) will increase these numbers but we will be one step closer to owning 100% of cash generating ability of the LDS conglomerate.

~S